Quality-of-life assessment in French ...
Type de document :
Compte-rendu et recension critique d'ouvrage
DOI :
PMID :
Titre :
Quality-of-life assessment in French patients with metastatic melanoma in real life
Auteur(s) :
Kandel, Marguerite [Auteur correspondant]
Institut Gustave Roussy [IGR]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Dalle, Stéphane [Auteur]
Centre de Recherche en Cancérologie de Lyon [UNICANCER/CRCL]
Bardet, Aurélie [Auteur]
Service de biostatistique et d'épidémiologie [SBE]
Institut Gustave Roussy [IGR]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Allayous, Clara [Auteur]
Immunologie humaine, physiopathologie & immunothérapie [HIPI (UMR_S_976 / U976)]
Mortier, Laurent [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Dutriaux, Caroline [Auteur]
Groupe hospitalier Saint-André
Guillot, Bernard [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Leccia, Marie Thérèse [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Dalac, Sophie [Auteur]
Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand [CHU Dijon]
Legoupil, Délphine [Auteur]
Centre Hospitalier Régional Universitaire de Brest [CHRU Brest]
Saiag, Phillippe [Auteur]
Hôpital Ambroise Paré [AP-HP]
Montaudie, Henri [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Arnault, Jean Philippe [Auteur]
Service de dermatologie [CHU d'Amiens-Picardie]
Brunet-Possenti, Florence [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Grob, Jean Jacques [Auteur]
Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM]
Dequatrebarbes, Julie [Auteur]
Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois]
Beylot-Barry, Marie [Auteur]
Service de dermatologie [Bordeaux]
Lesimple, Thierry P. [Auteur]
CRLCC Eugène Marquis [CRLCC]
Aubin, François F. [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Maubec, Eve [Auteur]
Granel-Brocard, Florence [Auteur]
Service de Dermatologie et Allergologie [CHRU Nancy]
Stoebner, Pierre Emmanuel [Auteur]
Centre Hospitalier Universitaire de Nîmes [CHU Nîmes]
Dupuy, Alain [Auteur]
Service de Dermatologie [Rennes] = Dermatology [Rennes]
Dreno, Brigitte [Auteur]
Service de dermatologie [Nantes]
Michiels, Stefan [Auteur]
Oncostat [U1018 (Équipe 2)]
Service de biostatistique et d'épidémiologie [SBE]
Institut Gustave Roussy [IGR]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Lebbe, Célèste [Auteur]
Centre Léon Bérard [Lyon]
Borget, Isabelle [Auteur]
Service de biostatistique et d'épidémiologie [SBE]
AP-HP. Université Paris Saclay
Institut Gustave Roussy [IGR]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Institut Gustave Roussy [IGR]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Dalle, Stéphane [Auteur]
Centre de Recherche en Cancérologie de Lyon [UNICANCER/CRCL]
Bardet, Aurélie [Auteur]
Service de biostatistique et d'épidémiologie [SBE]
Institut Gustave Roussy [IGR]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Allayous, Clara [Auteur]
Immunologie humaine, physiopathologie & immunothérapie [HIPI (UMR_S_976 / U976)]
Mortier, Laurent [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Dutriaux, Caroline [Auteur]
Groupe hospitalier Saint-André
Guillot, Bernard [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Leccia, Marie Thérèse [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Dalac, Sophie [Auteur]
Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand [CHU Dijon]
Legoupil, Délphine [Auteur]
Centre Hospitalier Régional Universitaire de Brest [CHRU Brest]
Saiag, Phillippe [Auteur]
Hôpital Ambroise Paré [AP-HP]
Montaudie, Henri [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Arnault, Jean Philippe [Auteur]
Service de dermatologie [CHU d'Amiens-Picardie]
Brunet-Possenti, Florence [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Grob, Jean Jacques [Auteur]
Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM]
Dequatrebarbes, Julie [Auteur]
Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois]
Beylot-Barry, Marie [Auteur]
Service de dermatologie [Bordeaux]
Lesimple, Thierry P. [Auteur]
CRLCC Eugène Marquis [CRLCC]
Aubin, François F. [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Maubec, Eve [Auteur]
Granel-Brocard, Florence [Auteur]
Service de Dermatologie et Allergologie [CHRU Nancy]
Stoebner, Pierre Emmanuel [Auteur]
Centre Hospitalier Universitaire de Nîmes [CHU Nîmes]
Dupuy, Alain [Auteur]
Service de Dermatologie [Rennes] = Dermatology [Rennes]
Dreno, Brigitte [Auteur]
Service de dermatologie [Nantes]
Michiels, Stefan [Auteur]
Oncostat [U1018 (Équipe 2)]
Service de biostatistique et d'épidémiologie [SBE]
Institut Gustave Roussy [IGR]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Lebbe, Célèste [Auteur]
Centre Léon Bérard [Lyon]
Borget, Isabelle [Auteur]
Service de biostatistique et d'épidémiologie [SBE]
AP-HP. Université Paris Saclay
Institut Gustave Roussy [IGR]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Titre de la revue :
Cancer
Pagination :
611-618
Éditeur :
Wiley
Date de publication :
2020
ISSN :
0008-543X
Mot(s)-clé(s) en anglais :
Clinical practice
Immunotherapy
Metastatic melanoma
Quality of life
Real-life
Targeted therapy
Immunotherapy
Metastatic melanoma
Quality of life
Real-life
Targeted therapy
Discipline(s) HAL :
Sciences du Vivant [q-bio]/Cancer
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Dermatologie
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Dermatologie
Résumé en anglais : [en]
Background: Significant progress was recently observed in the treatment of metastatic melanoma (MM). With >50% of patients now reaching a second line of treatment and a significant improvement in the survival rate, an ...
Lire la suite >Background: Significant progress was recently observed in the treatment of metastatic melanoma (MM). With >50% of patients now reaching a second line of treatment and a significant improvement in the survival rate, an assessment of quality of life (QoL) during the whole course of the disease becomes necessary. The objective of this study was to describe the QoL of patients with MM in France, from their diagnosis of advanced disease to their death, in real life. Methods: QoL data were collected through MelBase, a prospective, French, multicentric cohort dedicated to the follow-up of adults with MM. QoL was assessed using the EuroQoL-5D questionnaire and the Functional Assessment of Cancer Treatment (FACT)-Melanoma questionnaire at the time of study inclusion, every 3 months, and at the time of each treatment change until death. To assess longitudinal changes from baseline to death, mixed-effect models for repeated-measures analyses were used to control for baseline covariates. Results: QoL was assessed in 1435 patients who were included in the study between 2013 and 2018. The median follow-up was 9.4 months, and 47% of patients died during follow-up. During first-line treatment, the model-based, mean utility score was 0.830 (95% CI, 0.818-0.843), the mean FACT-General score was 77.22 (95% CI, 76.23-78.22), and the mean FACT-Melanoma score was 129.46 (95% CI, 128.02-130.90). At the time of a change in treatment line, there was a decrease of −0.027 (95% CI, −0.03, −0.02) in the utility score, −1.82 (95% CI, −1.88, −1.76) in the FACT-General score, and −2.98 (95% CI, −3.05, −2.91) in the FACT-Melanoma score compared with first-line treatment. Conclusions: In the MelBase cohort, the QoL among patients with MM seems to be fairly stable over the whole disease course, although a small but significant decrease at time therapy is changed is observed.Lire moins >
Lire la suite >Background: Significant progress was recently observed in the treatment of metastatic melanoma (MM). With >50% of patients now reaching a second line of treatment and a significant improvement in the survival rate, an assessment of quality of life (QoL) during the whole course of the disease becomes necessary. The objective of this study was to describe the QoL of patients with MM in France, from their diagnosis of advanced disease to their death, in real life. Methods: QoL data were collected through MelBase, a prospective, French, multicentric cohort dedicated to the follow-up of adults with MM. QoL was assessed using the EuroQoL-5D questionnaire and the Functional Assessment of Cancer Treatment (FACT)-Melanoma questionnaire at the time of study inclusion, every 3 months, and at the time of each treatment change until death. To assess longitudinal changes from baseline to death, mixed-effect models for repeated-measures analyses were used to control for baseline covariates. Results: QoL was assessed in 1435 patients who were included in the study between 2013 and 2018. The median follow-up was 9.4 months, and 47% of patients died during follow-up. During first-line treatment, the model-based, mean utility score was 0.830 (95% CI, 0.818-0.843), the mean FACT-General score was 77.22 (95% CI, 76.23-78.22), and the mean FACT-Melanoma score was 129.46 (95% CI, 128.02-130.90). At the time of a change in treatment line, there was a decrease of −0.027 (95% CI, −0.03, −0.02) in the utility score, −1.82 (95% CI, −1.88, −1.76) in the FACT-General score, and −2.98 (95% CI, −3.05, −2.91) in the FACT-Melanoma score compared with first-line treatment. Conclusions: In the MelBase cohort, the QoL among patients with MM seems to be fairly stable over the whole disease course, although a small but significant decrease at time therapy is changed is observed.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Source :